Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL860157 | 0.73 | KCNH2 (0.58) | TLR8KCNH2PDE10ASMN1; SMN2LMNA | |
| SCHEMBL797638 | 0.71 | KCNH2 (0.61) | TLR8KCNH2PDE10ASMN1; SMN2LMNA | |
| SCHEMBL29903853 | 0.71 | KCNH2 (0.61) | TLR8KCNH2PDE10ASMN1; SMN2LMNA | |
| SCHEMBL29903876 | 0.71 | KCNH2 (0.61) | TLR8KCNH2PDE10ASMN1; SMN2LMNA | |
| SCHEMBL6114801 | 0.71 | KCNH2 (0.61) | TLR8KCNH2PDE10ASMN1; SMN2LMNA | |
| SCHEMBL5367040 | 0.71 | KCNH2 (0.61) | TLR8KCNH2PDE10ASMN1; SMN2LMNA | |
| SCHEMBL6115276 | 0.71 | KCNH2 (0.61) | TLR8KCNH2PDE10ASMN1; SMN2LMNA | |
| SCHEMBL2514450 | 0.71 | KCNH2 (0.61) | TLR8KCNH2PDE10ASMN1; SMN2LMNA | |
| SCHEMBL6115301 | 0.71 | KCNH2 (0.61) | TLR8KCNH2PDE10ASMN1; SMN2LMNA | |
| SCHEMBL6114960 | 0.71 | KCNH2 (0.61) | TLR8KCNH2PDE10ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009498-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | NITROMED, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20060063774-A1 | Phosphodiesterase inhibitor compounds and nitric oxide donors | GARVEY DAVID S | 2006-03-23 | — | — | US | disclosed |
| EP-1109543-A4 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6930113-B2 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2005-08-16 | — | — | US | disclosed |
| US-20040087591-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | GARVEY DAVID S (US) | 2004-05-06 | — | — | US | disclosed |
| US-20030158184-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses | GARVEY DAVID S (US) | 2003-08-21 | — | — | US | disclosed |
| US-20030023087-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | GARVEY DAVID S (US) | 2003-01-30 | — | — | US | disclosed |
| US-6472425-B1 | Methods for treating female sexual dysfunctions | NITROMED, INC. | 2002-10-29 | — | — | US | disclosed |
| US-6462044-B2 | THERAPY FOR SEXUAL DISORDERS | NITROMED, INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020019405-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | GARVEY DAVID S (US) | 2002-02-14 | — | — | US | disclosed |
| US-6177428-B1 | TREATMENT OF SEXUAL DYSFUNCTION; STIMULATION OF ENDOGENOUS NITROGEN MONOXIDE SYNTHESIS | NITROMED, INC. | 2001-01-23 | — | — | US | disclosed |
| US-6172068-B1 | SEXUAL DISORDERS | NITROMED, INC. | 2001-01-09 | — | — | US | disclosed |
| US-6172060-B1 | THERAPY FOR SEXUAL DISORDERS | NITROMED, INC. | 2001-01-09 | — | — | US | disclosed |
| US-6133272-A | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses | NITROMED, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| WO-2000012076-A9 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2000-08-17 | — | — | WO | disclosed |
| EP-0941086-A4 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITOR COMPOUNDS, COMPOSITIONS AND THEIR USES | NITROMED INC (US) | 2000-07-12 | — | — | EP | disclosed |
| WO-2000012076-A1 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | disclosed |
| EP-0941086-A1 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITOR COMPOUNDS, COMPOSITIONS AND THEIR USES | Nitromed, Inc. (US) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998019672-A9 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITOR COMPOUNDS, COMPOSITIONS AND THEIR USES | — | 1998-09-11 | — | — | WO | disclosed |
| WO-1998019672-A1 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITOR COMPOUNDS, COMPOSITIONS AND THEIR USES | NITROMED INC. (US) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023087-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | PDE3A, PDE5A, PTGIS | TLR8 4303/4885KCNH2 867/4885CYP19A1 61/4885 |
| US-20020019405-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | PDE3A, PDE5A, PTGIS | TLR8 4303/4885KCNH2 867/4885CYP19A1 61/4885 |
| US-20080009498-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | PDE3A, PDE3B, PDE2A | TLR8 3231/4885KCNH2 1819/4885CYP19A1 66/4885 |
| US-20040087591-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | PDE3A, PDE3B, PDE5A | TLR8 3837/4885KCNH2 703/4885CYP19A1 88/4885 |
| US-20030158184-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses | PDE3A, PDE3B, PDE2A | TLR8 4483/4885KCNH2 2463/4885CYP19A1 64/4885 |
| US-20060063774-A1 | Phosphodiesterase inhibitor compounds and nitric oxide donors | PDE3B, PDE3A, PDE5A | TLR8 3767/4885KCNH2 1962/4885CYP19A1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.